Context:

Nike’s turnaround remains elusive as China weakness darkens the outlook, with investors pressured by guidance for continued declines through the year and a sizable drop in China expected to offset NA gains. The company projected a low-single-digit sales decline for the year and a 2%–4% drop next quarter, with China plunging around 20% despite a small FX tailwind. Executives warned gross margins may only begin to stabilize late in fiscal 2027 amid rising input costs and ongoing assortment cleanups in China. With multiple business reforms still in play and macro headwinds mounting, analyst patience has dwindled and major banks downgraded the stock. The forward narrative remains uncertain, though leadership insists the path to growth is intact and closer, even as timing remains unclear.

Dive Deeper:

• Nike reported fiscal Q3 results showing that investors did not see tangible proof of a sustainable recovery, sending shares down more than 14% in intraday trading. Management signaled sales would slip by a low single-digit percentage through the end of the calendar year, driven by a downturn in China offsetting North American strength.

• Guidance calls for 2%–4% sales decline in the current quarter, worse than the 1.9% growth consensus, with China sales expected to fall about 20% despite a modest two-point foreign exchange benefit.

• Efforts to prune and price Nike’s China assortment are expected to continue and dampen revenue growth through fiscal 2027, with lapping the tariff impact in fiscal 2027 anticipated to help year-over-year comparisons.

• Gross margins have declined year over year for seven straight quarters and may not reset quickly due to higher product input costs tied to the ongoing Middle East disruption and rising oil prices, according to management.

• Executives stressed near-term resilience in North America and wholesale channels but provided no firm timeline for a return to sustained growth, noting a broader, more complex turnaround across the business.

• Analysts from Goldman Sachs, JP Morgan, and Bank of America downgraded the stock, citing a dragging turnaround, continued headwinds, and dwindling patience as the catalyst timing shifts further out.

• Management remains confident the company is on track to regain balanced growth in North America, though the cadence and scope of improvements remain uncertain and subject to macro volatility.